PHARMACOGENOMICS HYPERTENSION :A NEW APPROACH FOR PERSONALIZED MEDICINE ( PGX - HT ) - PGX-HT

OSPEDALE SAN RAFFAELE0 个研究点开始时间: 2016年9月30日最近更新: 2016年10月3日

适应症

试验速览

暂无简介。

•Patients aged between 25 and 60 years with newly diagnosed mild to moderate essential hypertension ( systolic blood pressure between 140 and 160 mmHg and diastolic blood pressure between 90 and 110 mmHg measured as the average of three consecutive measurements )
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 300
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Known causes of secondary hypertension ;
•- Pregnant women , nursing mothers or women of childbearing age taking anti - contraceptives ;
•- Severe hypertension or malignant ;
•- History of kidney disease ;
•- Significant renal disease ( creatinine clearance less than 60 ml / min ) ; anuria .
•- Hypokalemia or hyponatremia refractory ;
•- Hypercalcemia ;
•-iperuricemia symptomatic ;
•- Liver disease ;
•- Heart disease ( myocardial infarction , atrial fibrillation , etc. ) ;
•- Diabetes ( fasting glucose > 125 mg / dL ) ;
•- Treatment with statins ;
•- Obesity ( BMI > 30 kg / m2 ) ;
•-HYPERSENSITIVITY known to the study drugs ( ACE inhibitors , hydrochlorothiazide , sulphonamide derivatives ) or any of the excipients .
•-patients not capable of giving valid consent

发起方

OSPEDALE SAN RAFFAELE